^
Association details:
| Biomarker: | KRAS amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
RAS amplification as a negative predictor of benefit from anti-EGFR containing therapy regimens in metastatic colorectal cancer
Published date:
01/19/2021
Excerpt:
Genomic analysis was performed using the Foundation Medicine (FM) comprehensive genomic profiling (CGP) database (GDB) of 37,233 CRC cases….COH cohort, six patients with RASa (13‐54 copies) received EGFRmAb; 4/6 had progressive disease, 2 had stable disease; median time to treatment discontinuation (TTD) was 2.5 months.
DOI:
10.1002/onco.13679
